Margaret K Hahn, MD PhD

Centre for Addiction and Mental Health Central insulin to prevent olanzapine-induced adiposity: a rodent model Atypical antipsychotic (AAP) medications, the mainstay treatment for psychosis and schizophrenia, are defined by weight gain and metabolic problems that likely contribute to a 2-fold increase in cardiovascular (CV) deaths in this population.